Bid, but not Bax, regulates VDAC channels

Tatiana K Rostovtseva1, Bruno Antonsson, Motoshi Suzuki

  • 1Laboratory of Physical and Structural Biology, NICHD, National Institutes of Health, Bethesda, Maryland 20892, USA. rostovts@helix.nih.gov

Insights

The pro-apoptotic protein Bax does not appear to trigger cytochrome c release by interacting with the voltage-dependent anion channel (VDAC). However, cleaved Bid protein does affect VDAC function, potentially disrupting mitochondrial metabolite exchange.

Area of Science:

  • Cell Biology
  • Biophysics
  • Molecular Biology

Background:

  • Cytochrome c release from mitochondria is a key event in apoptosis.
  • The voltage-dependent anion channel (VDAC) is implicated in mitochondrial outer membrane permeabilization.
  • Conflicting mechanisms exist regarding VDAC's role in cytochrome c release.

Purpose of the Study:

  • To investigate the interaction between the pro-apoptotic protein Bax and VDAC.
  • To determine if Bax mediates cytochrome c release through VDAC.
  • To examine the effect of other pro-apoptotic proteins, like Bid, on VDAC function.

Main Methods:

  • Reconstitution of mammalian VDAC channels into planar phospholipid membranes.
  • Electrophysiological recordings of VDAC channel properties.
  • Addition of monomeric and oligomeric Bax to reconstituted VDAC.
  • Treatment of reconstituted VDAC with caspase-8 cleaved Bid.

Main Results:

  • Bax, in monomeric or oligomeric forms, did not alter VDAC channel properties.
  • No electrophysiologically detectable interaction was observed between Bax and VDAC.
  • Caspace-8 cleaved Bid induced VDAC channel closure, affecting voltage gating.

Conclusions:

  • Bax does not induce cytochrome c release by directly acting on VDAC.
  • Bid may contribute to mitochondrial dysfunction by altering VDAC gating and metabolite transport.
  • VDAC's role in apoptosis may be modulated by different pro-apoptotic proteins through distinct mechanisms.

Related Concept Videos

Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...